COMPARE
Three Compounds, Three Very Different Evidence Bases
Lined up side by side on mechanism, human trial depth, regulatory status and what "lab-grade" actually means for each one.
The short version
These three compounds are not interchangeable, even though vendors sometimes bundle them together as "research peptides." GHK-Cu is a naturally occurring copper-binding tripeptide, best documented as a topical cosmetic ingredient. Ipamorelin is a synthetic growth-hormone secretagogue with a very thin human trial record. Tesamorelin is a synthetic hormone analogue with a genuine FDA approval and a real regulatory dossier behind it.
Those differences matter most for the question this hub asks: what does "lab-grade" or "high purity" actually buy a reader for each one. A purity certificate means something different attached to an FDA-regulated drug than attached to an unregulated research-chemical vial, and the table below is organized around that distinction as much as around mechanism.
Mechanism, at a glance
| Compound | Class | Primary mechanism | Route best studied |
|---|---|---|---|
| GHK-Cu | Copper-binding tripeptide | Stimulates fibroblast collagen/elastin synthesis; broad gene-expression shift toward repair pathways [2][6] | Topical (cosmetic) |
| Ipamorelin | Growth-hormone secretagogue | Selectively activates the ghrelin receptor (GHS-R1a) on pituitary cells, triggering a GH pulse without raising cortisol or prolactin [11] | Subcutaneous / IV (research) |
| Tesamorelin | GHRH analogue | Binds the GHRH receptor on pituitary somatotrophs, amplifying the body's own pulsatile GH release [16] | Subcutaneous (approved drug) |
Evidence maturity
| Compound | Deepest human evidence | Largest trial in this dataset | Regulatory status |
|---|---|---|---|
| GHK-Cu | Small topical trials (n roughly 13-71) | 45-person hair-growth RCT of a combination formula [3] | Legal cosmetic ingredient; no drug approval for any route |
| Ipamorelin | One short Phase 2 trial, primary endpoint missed | 114-person postoperative-ileus RCT [10] | Never approved as a drug; removed from the 503A compounding list in 2024 |
| Tesamorelin | Multiple RCTs plus a 2026 meta-analysis of five pooled trials [13] | 273-person, 52-week program [17] | FDA-approved (NDA, 2010) for HIV-associated lipodystrophy |
On raw evidence volume, tesamorelin is furthest along, GHK-Cu sits in the middle with a long but mostly cosmetic-topical record, and ipamorelin has the least — a single human efficacy trial that did not hit its primary endpoint [10].
What 'lab-grade' means for each
For tesamorelin, the approved product is manufactured under FDA quality-control requirements — identity, purity and batch consistency are a condition of approval, not a marketing claim. For GHK-Cu, the strongest quality assurance sits with topical cosmetic manufacturing standards, which are real but distinct from pharmaceutical drug-grade requirements; injectable research-grade GHK-Cu carries no equivalent oversight [1]. For ipamorelin, there is no approved product at all — every batch sold today is research-grade material from an unregulated supplier, and the only investigational-grade batch that has ever been through controlled human testing was made specifically for the 2014 trial, not what circulates in research-chemical markets [10].
Across all three, a chromatography certificate reporting a high purity percentage answers a narrow question — what was in that specific batch on the day it was tested — and does not answer the broader one a reader usually wants answered: whether the compound has been shown, in controlled human trials, to do what it is marketed to do.
Reading the safety literature across all three
Tesamorelin's safety picture is the most complete: a dedicated NIH liver-safety monograph rates it an unlikely cause of liver injury [14], and its pooled trial data show no excess of serious adverse events [13]. Ipamorelin's safety picture leans heavily on class-level signals borrowed from related compounds — most notably a cardiotoxicity finding in a structurally different GHS-R1a agonist, not ipamorelin itself — because no long-duration ipamorelin-specific safety study exists in any species [9]. GHK-Cu's caution set is almost entirely about topical use — irritation, formulation stability with other actives — with injectable or systemic use flagged as effectively unstudied in humans [1].
Read each compound's own page — GHK-Cu, ipamorelin, tesamorelin — for the full findings and cautions, or the frequently asked questions for shorter, direct answers.